Oncolytics Biotech (ONCY) - 2023 Q1 - Quarterly Report

Oncolytics Biotech Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights ® Pancreatic Cancer Program Reported a 69% ORR and confirmed complete response in phase 1/2 GOBLET trial's pancreatic cancer cohort Pancreatic cancer program advancing towards registration path supported by phase 1/2 GOBLET data showing a confirmed complete response and 69% objective response rate in advanced/metastatic patients Phase 2 BRACELET-1 trial in HR+/HER2- metastatic breast cancer on track for ...